Pharmacological Treatments for Arthritis

Arthritis is an umbrella term encompassing various inflammatory joint diseases that currently present a considerable threat to the global population, with millions of people of all ages and origins being affected. Arthritis is a degenerative disease of joints that results in pain, stiffness, and limited mobility; it has different types, such as osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. Although each subtype's pathology may differ, inflammation of the synovial membrane and cartilage erosions are characteristic. Currently, there is no cure for arthritis; therefore, the main goal of treatment is to minimize pain, maintain joint stability, and enhance the patient's quality of life. This goal is at the center of pharmacological interventions, which have a repertoire of drugs that target pain and inflammation, progression of the disease, and protection of the joints. However, the choice of pharmacotherapy should be based on the type and severity of arthritis, the presence of other diseases, and the patient's preferences. Furthermore, managing arthritis could require pharmacological and non-pharmacological methods, including exercise, physical therapy, and patient education. This paper aims to discuss the available pharmacological therapies in arthritis, their mechanisms of action, effectiveness, side effects, and other relevant aspects.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Nonsteroidal anti-inflammatory drugs (NSAIDs) constitute a large group of drugs commonly used in the treatment of arthritis due to their very effective action against inflammation and pain. NSAIDs reduce the cyclooxygenase enzymes, which in turn interferes with the production of prostaglandins, essential inflammatory and pain-regulating substances. This mechanism forms the basis of their effectiveness in managing the symptoms of different types of arthritis, including OA and inflammatory arthritis. They suppress the action of cyclooxygenase (COX) enzymes and, therefore, decrease the production of prostaglandins, which play a critical role in the inflammation and pain processes. To this end, nonselective NSAIDs like ibuprofen, naproxen, and diclofenac for osteoarthritis (OA) have been established to offer relief of symptoms in several different types of arthritis. In a research conducted by Zeng et al. (2021), it was revealed that NSAIDs are effective in managing pain and functional status in patients with OA and RA and have similar analgesic efficacy to opioids but lower risks of side effects.

However, its use is accompanied by considerable risks to the gastrointestinal (GI) tract and the cardiovascular system. Prolonged usage of NSAIDs has been associated with increased peptic ulcer formation, gastrointestinal hemorrhage, and perforation with the risk of complications such as hemorrhage or perforation (Fraenkel et al., 2020). To avoid these risks, new selective COX-2 inhibitors like celecoxib were introduced as agents that selectively target the COX-2 enzyme without affecting the COX-1, leading to lesser GI side effects Nawaz et al. (2020) found that that COX-2 selective agents had a significantly reduced risk of gastrointestinal adverse effects than conventional NSAIDs. While they are effective in pain relief, NSAIDs also have cardiovascular side effects such as myocardial infarction and stroke. Zeng et al. (2021), in their research, pointed out that traditional NSAIDs and COX-2 inhibitors are associated with cardiovascular events, and this risk is higher with increasing dose and duration of use. Therefore, the decision to prescribe NSAID should involve patient-specific characteristics such as cardiovascular risk factors and history of gastrointestinal disorders. The minimal effective dose should be used for the shortest time.

Furthermore, the use of NSAIDs has been related to cardiovascular adverse effects such as elevated myocardial infarction risk and stroke risk. This cardiovascular safety concern led to the design of selective COX-2 inhibitors such as celecoxib since these drugs selectively block the COX-2 isoenzyme involved in inflammation without affecting the COX-1 enzyme that maintains the integrity of the GI lining. According to Fraenkel et al. (2020), although COX-2 selective non-steroidal anti-inflammatory drugs have been shown to have a lower risk of gastrointestinal side effects compared to conventional NSAIDs, they continue to be a source of concern regarding their cardiovascular side effects. Selective COX-2 inhibitors have raised concerns about cardiovascular safety, as evidenced by meta-analyses and some observational studies. This means that attention should be paid to the patient's risk factors and adherence to the guidelines for prescribing such drugs. Regarding the NSAID selection in clinical practice, several considerations must be made, including the type of arthritis, the severity of the disease, the presence of comorbid conditions, and patient-specific factors (Nawaz et al., 2020; Zeng et al., 2021). It is, therefore, imperative that patients' responses to NSAIDs be treated individually when determining the therapeutic benefits of the drugs versus their risks and that clients' providers be available to discuss these matters. Additionally, more sequential efforts in pharmacovigilance and research are still required to unravel the differential cardiovascular and gastrointestinal risk profiles and benefits of different NSAIDs in real-world practice for patients with arthritis.

Disease-modifying antirheumatic Drugs (DMARDs)

DMARDs are central to treating RA and other autoimmune arthritic diseases, primarily controlling inflammation, preventing disease activity, and conserving joint integrity. Methotrexate, one of the conventional synthetic DMARDs (csDMARDs), has shown higher efficacy and safety than other csDMARDs in many clinical trials and observational studies. Zhao et al. (2022) that showed that methotrexate has superior efficacy to placebo and other csDMARDs in decreasing disease activity, enhancing physical function, and preventing radiographic progression of RA. Furthermore, methotrexate is considered the first-choice treatment in the management of RA mainly because it is effective, safe, and relatively inexpensive. Other csDMARDs include sulfasalazine, hydroxychloroquine, and leflunomide, which act as either substitutes or complements to methotrexate in RA treatment due to the contraindications posed by the latter (Freitas et al., 2020). Second-line therapies, such as biologic DMARDs, include TNF inhibitors, IL-6 inhibitors, and B-cell depleting agents for patients with csDMARD-inadequate responses. These have changed the treatment paradigms for RA and other autoimmune arthritis by offering superior disease management and outcomes (Freitas et al., 2020). However, their use is associated with an increased risk of infections and other complications that require proper patient selection and close monitoring of the patient's status.

Corticosteroids

According to Paglia et al. (2021), corticosteroids are helpful in arthritis, especially when given at the proper doses and at the right time, to reduce inflammation and enhance the overall health and prognosis of the condition. These drugs work by inhibiting immune mechanisms and decreasing the generation of cytokines that cause inflammation and pain in the damaged joint. Intra-articular corticosteroids are preferred for patients with specific joint inflammation, and they provide short-term, localized pain relief with fewer systemic side effects. Multiple research articles have shown that corticosteroid injections offer significant benefits in pain and function in OA and inflammatory arthritis. For example, Maity et al. (2021) found out that articular corticosteroid injections offered considerable analgesic and function recovery in patients with knee OA that could last several months to years. However, the long-term systemic use of corticosteroids is characterized by many complications, such as osteoporosis, diabetes, hypertension, and increased vulnerability to infections. Thus, corticosteroids may be used short-term or as a part of combined therapeutic protocols and disease-modifying antirheumatic drugs in treating chronic arthritic conditions (Paglia et al., 2021; Nawaz et al., 2020). The dose and duration of corticosteroids should be tailored to the patient's condition, co-morbidities, and clinical response to treatment to minimize side effects while maximizing the therapeutic benefits.

Biologic Agents

Biologic agents have emerged as the new class of arthritis therapy that directly affects the pathogenetic cytokines within arthritis diseases. Tumor necrosis factor (TNF) blockers, including adalimumab, etanercept, and Infliximab, are among the most commonly used biological agents and have shown effectiveness in the management of RA and other inflammatory joint diseases in terms of decreasing disease activity, slowing joint damage detected by radiography and improving clinical outcomes (Cho et al., 2023). Zeng et al. (2020) performed a systematic review and meta-analysis of randomized controlled trials of TNF inhibitors for RA. They reported that TNF inhibitors were significantly more effective than placebo and DMARDs in attaining clinical remission and preventing radiographic progression of RA. Furthermore, biologic agents that act on IL-6, including tocilizumab, or which target B cells, such as rituximab, are other treatment options in patients who have shown an inadequate response to TNF inhibitors or other DMARDs (Cho et al., 2023). Nonetheless, utilizing biological agents exposes patients to higher risks of bacterial, viral, and fungal infections and tuberculosis reactivation. Furthermore, they can develop antibodies against the drugs, making the treatment ineffective in the long run; hence, monitoring the patients and adjusting treatment plans accordingly is crucial.

Future Directions and New Strategies

New therapeutic strategies present promising approaches to arthritis pharmacotherapy because they are still in the development stage and can attempt to solve the existing problems and limitations of the medical treatment of arthritis (Zeng et al., 2020). According to Sarabia et al. (2022), Janus kinase (JAK) inhibitors are a novel class of agents that target intracellular signaling cascades implicated in inflammation and may provide a rational approach to reducing disease activity in rheumatoid arthritis (RA) and other autoimmune arthritides. Randomized controlled trials have shown that JAK inhibitors, including tofacitinib and baricitinib, have positive effects on disease activity and clinical outcomes in RA patients who have not responded to conventional DMARDs or biologic agents. Furthermore, available small molecule inhibitors directed towards specific cytokines or signaling pathways involved in arthritis are still developing. They may be useful for patients resistant to traditional therapies. According to Zoltán Szekanecz et al. (2024), precision medicine strategies using genetic and molecular biomarkers can determine which patients will most likely benefit from specific treatments, enhancing treatment efficacy and decreasing time spent on ineffective treatments. Furthermore, promising research in regenerative medicine, such as stem cell therapy and tissue engineering, presents a potential cure for arthritis through repairing damaged joint tissues. Although these novel therapies are still in the clinical development and optimization stage, they may hold promise for enhancing the accuracy, effectiveness, and durability of arthritis management in the foreseeable future.

Conclusion

Conclusively, pharmacological interventions form a fundamental part of comprehensive arthritis management with the aim of offering symptomatic relief, halting disease progression, and improving the quality of life of affected individuals. NSAIDs, DMARDs, corticosteroids, and biologic agents are the mainstays of arthritis management, each having distinct advantages and potential drawbacks. However, the treatment of arthritis is rapidly changing now, and new therapies like JAK inhibitors and the humanized immune system approaches to drug targeting have been introduced to make it more precise and effective. The application of genetic and molecular biomarkers in discovering new treatments indicates that customization of treatment plans should be specific to individual patients to achieve the best results with minimal side effects. Moreover, stem cell research's current development for regenerative medicine applications can also change how arthritis is approached and treated.